The Covid-19 Pandemic

 

The Covid-19 pandemic has created an immediate worldwide need for consumer health self-monitoring technologies. As with any viral infection, one of the first signs of illness is the onset of a fever. Ideally, fever monitoring is done by patients at-home using their phones.

Gentag, Inc. and its patent holding company, Altivera, LLC, are experienced in the area of wireless self-monitoring technologies, having predicted the Near Field Communication (NFC) consumer diagnostics cell phone markets in 2003.

GENTAG / ALTIVERA COVID-19 Screening Technologies and Intellectual Property

 

 

Gentag has worldwide patents in several key areas related to the virus. These patented technologies cover the consumer self-diagnostic health markets with cell phones. Specifically the patented Gentag/Altivera technologies related to Covid-19 include the following:

FEVER MONITORING

  1. NFC / Bluetooth fever patches (licensed)
  2. Optical blockchain fever patches

RAPID DIAGNOSTIC TESTS (ANTIBODIES AND ANTIGENS)

  1. NFC / Bluetooth lateral flow immunoassays
  2. Optical blockchain immunoassays

ADVANCED DIAGNOSTIC TESTS

  1. NFC / Bluetooth Lab-on-a-Chip
  2. NFC / Bluetooth biomarker diagnostic skin patches
  3. Optical Virus Detector (Asymptomatic Cases)

MEDICATION MONITORING

  1. Biologic/biosimilar drug compliance monitoring platform
  2. Drug authentication platform

Partnerships are currently being discussed with a number of companies on these individual technology areas related to the virus. The Gentag/Altivera IP offers is a unifying patented platform allowing a company to take the lead in the Covid-19 markets, as well as future markets for consumer health self-monitoring using cell phones.